RaDaR assay is a multi-tumor personalized NGS assay that tracks a set of up to 48 tumor-specific variants in a patient using a liquid biopsy with exceptional sensitivity, allowing both detection of residual disease following curative intent or definitive treatment and early detection of relapse. It accelerates processing time 4-fold, increases sample throughput 20-fold and requires 50-fold less starting material than the current standard. It can be used to detect topoisomerase 1-DNA adducts in as little as 60 ng of DNA, corresponding to 10 000 human cells.
Hematological Malignancies, Non Small Cell Lung Cancer
Next-Generation Sequencing (NGS)